ArticleFrontiers in pharmacology2022

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer.

Xia Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.